Фибрилляция предсердий у пациентов с хронической болезнью почек
https://doi.org/10.35336/VA-2019-3-47-52
Аннотация
В настоящем обзоре рассмотрены особенности структуры, патогенеза и лечения фибрилляции предсердий у пациентов с выраженной хронической болезнью почек.
Об авторах
Н. П. Мельников
ФГБУ «ВЦЭРМ им. А.М.Никифорова» МЧС России
Россия
Россия
Мельников Николай Павлович
Санкт-Петербург
С. М. Яшин
Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия
Санкт-Петербург
Россия
Санкт-Петербург
Список литературы
1. Lau Y.C., Lip G.Y. Management of Atrial Fibrillation in Patients With Kidney Disease. // J Atr Fibrillation - 2014 Apr 30;6(6):989.
2. Khouri Y., Stephens T., Ayuba G. et al. Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. // J Atr Fibrillation. 2015 Apr-May; 7(6): 62-69.
3. Есаян А.М. Антикоагулянтная терапия у пациента с хронической болезнью почек и фибрилляцией предсердий. // Сердечная недостаточность. 2017; 18(4): 243252
4. Мухин Н.А., Смирнов А.В., Кобалава Ж.Д. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. // Российский Кардиологический Журнал. 2014;8 (112):7-37
5. Ronco C., McCullough P., Anker S.D. et al. Cardio-renal syndromes: reports from the consensus conference of the acute dialysis quality initiative. // Eur Heart J 2010; 31: 703-711.
6. Turakhia M.P., Blankestijn P.J., Carrero J.J. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference // Eur Heart J. 2018 Jun 21; 39(24): 2314-2325.
7. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. // Eur Heart J (2016) 37 (38): 2893-2962.
8. Roy-Chaudhury P., Tumlin J.A., Koplan B.A. et al. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. // Kidney International - 2018, 93, 941-951.
9. Abuhasira R., Mizrakli Y., Shimony A. et al., Atrial Fibrillation Characteristics in Patients on Haemodialysis vs. Peritoneal Dialysis. // Sci Rep. - 2018 Feb 14;8(1):2976.
10. Thongprayoon C., Chokesuwattanaskul R., Bathini T. et al. Epidemiology and Prognostic Importance of Atrial Fibrillation in Kidney Transplant Recipients: A Meta-Analysis. // J. Clin. Med. - 2018, 7, 370.
11. Huang S.Y., Chen Y.A., Chen S.A. et al. Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial Fibrillation. // Acta Cardiol. Sin. - 2016;32:259-264.
12. Vincenti A., Passini E., Fabbrini P. et al. Recurrent intradialytic paroxysmal atrial fibrillation: hypotheses on onset mechanisms based on clinical data and computational analysis. // Europace (2014) 16, 396-404.
13. Шишкова В.Н. Хроническая болезнь почек и сердечно-сосудистая заболеваемость: фокус на фибрилляцию предсердий. // Рациональная фармакотерапия в кардиологии 2015;11(2): 196-201
14. Chan K.E., Giugliano R.P., Patel M.R. et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. // J Am Coll Cardiol. - 2016 -Jun 21;67(24):2888-99.
15. Харламова У.В., Ильичева О.Е. Показатели гемостаза у больных с гипергомоцистеинемией на гемодиализе. // Бюллетень сибирской медицины. 2011; 10(1):127-131
16. Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. // European Heart Journal. 2011;32 (19):2387-2394.
17. Deal E.N., Pope H., Ross W. Apixaban use among patients with severe renal impairment. // Ann Pharmacother. - 2014;1648:1667.
18. Stanton B.E., Barasch N.S., Tellor K.B. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. // Pharmacotherapy. 2017; 37:412-419.
19. Mavrakanas T.A., Samer C.F., Nessim S.J., et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. // J Am Soc Nephrol. - 2017; 28:2241-2248.
20. Reed D., Palkimas S., Hockman R., et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. // Res Pract Thromb Haemost. - 2018;2:291-298.
21. Siontis K.C., Zhang X., Eckard A. et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. // Circulation. 2018; 138:1519-29.
22. Garg L., Chen C., Haines D.E. Atrial fibrillation and chronic kidney disease requiring hemodialysis - Does warfarin therapy improve the risks of this lethal combination? // Int J Cardiol. 2016 Nov 1;222:47-50.
23. Coleman C.I., Kreutz R., Sood N.A. et al., Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. // Am J Med. 2019 Sep;132(9):1078-1083.
24. Reinecke H., Jurgensmeyer S., Engelbertz C., et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronichaemodialysis: the AXADIAAFNET 8 study. // BMJ Open 2018 September 8(9) e022690.
25. January C.T., Wann L.S., Calkins H. et al. Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation // J Am Coll Cardiol. - 2019 Jul 9;74(1):104-132.
26. Potpara T.S., Jokic V., Dagres N. et al. Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy. // Med Chem. 2016;23(19):2070-83.
27. Sairaku A., Yoshida Y., Kamiya H. et al. Outcomes of ablation of paroxysmal atrial fibrillation in patients on chronic hemodialysis. // J Cardiovasc Electrophysiol. 2012 Dec;23(12):1289-1294.
28. Hayashi M., Kaneko S., Shimano M. et al. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. // Nephrol Dial Transplant. 2014 Jan;29(1):160-167.
29. Takigawa M., Kuwahara T., Takahashi A. et al. The impact of haemodialysis on the outcomes of catheter ablation in patients with paroxysmal atrial fibrillation. // Europace, 2014 Mar;16(3):327-34.
30. Regoli F., Araco M., Moccetti T. et al., Potential Clinical Utility and Feasibility of Combined Left Atrial Appendage Closure and Positioning of Miniaturized Pacemaker Through a Single Right Femoral Vein Access. // Am J Cardiol. - 2017 Jul 15;120(2):236-242.
31. Genovesi S., Slaviero G., Porcu L. et al. Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population. // Int J Cardiol. 2018 Jul 1, Volume 262, Pages 38-42.
32. Ajam F., Patel S., Alrefaee A. et al. Cardiac Arrhythmias in Patients with End Stage Renal Disease (ESRD) on Hemodialysis; Recent Update and Brief Literature Review. // Am J of Int Medicine. - 2019. - Vol. 7, No. 1. - pp. 22-26.
Рецензия
Для цитирования:
Мельников Н.П., Яшин С.М. Фибрилляция предсердий у пациентов с хронической болезнью почек. Вестник аритмологии. 2019;26(4):47-52. https://doi.org/10.35336/VA-2019-3-47-52
For citation:
Melnikov N.P., Yashin S.M. Atrial fibrillation in patients with chronic kidney disease. Journal of Arrhythmology. 2019;26(4):47-52. (In Russ.) https://doi.org/10.35336/VA-2019-3-47-52
Просмотров:
408
Послать статью по эл. почте 